Synaptonemal complex protein 3 as a novel prognostic marker in early stage non-small cell lung cancer
- Authors
- Chung, Joon-Yong; Kitano, Haruhisa; Takikita, Mikiko; Cho, Hanbyoul; Noh, Kyung Hee; Kim, Tae Woo; Ylaya, Kris; Hanaoka, Jun; Fukuoka, Junya; Hewitt, Stephen M.
- Issue Date
- 4월-2013
- Publisher
- W B SAUNDERS CO-ELSEVIER INC
- Keywords
- Immunohistochemistry; Non-small cell lung cancer; Prognostic marker; Synaptonemal complex protein 3; Tissue microarray
- Citation
- HUMAN PATHOLOGY, v.44, no.4, pp.472 - 479
- Indexed
- SCIE
SCOPUS
- Journal Title
- HUMAN PATHOLOGY
- Volume
- 44
- Number
- 4
- Start Page
- 472
- End Page
- 479
- URI
- https://scholar.korea.ac.kr/handle/2021.sw.korea/103581
- DOI
- 10.1016/j.humpath.2012.06.018
- ISSN
- 0046-8177
- Abstract
- Synaptonemal complex protein 3 is a marker for cell transformation that has prognostic significance in various cancers. However, the prognostic significance of synaptonemal complex protein 3 has not been studied in non-small cell lung cancer. To investigate the potential correlation between synaptonemal complex protein 3 and various clinicopathologic parameters, we assessed the expression of synaptonemal complex protein 3 in archival tumor tissues from 258 patients with non-small cell lung cancer by immunohistochemical staining. By immunofluorescence, synaptonemal complex protein 3 was detected in both the cytoplasmic and nuclear fractions of NCI-H1299 cell. In tumor samples, synaptonemal complex protein 3 is detected as cytoplasmic expression pattern and observed in 50 clinical samples (19.4%) by immunohistochemical staining. Synaptonemal complex protein 3 expression was correlated with T status (P = .008), lymph node metastasis (P = .010), tumor types (P = .019), and pleural invasion (P = .005). In multivariate analysis of patients with early stage disease, increased synaptonemal complex protein 3 expression predicted worse overall survival in early stage (stage I and II) with pT1 status (P = .041). These results suggest that positive synaptonemal complex protein 3 expression is a portent of poor outcome and may be a potential biomarker in the early stages of the non-small cell lung cancer for survival and may provide clues in the identification of patients for adjuvant therapy. Published by Elsevier Inc.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - Graduate School > Department of Biomedical Sciences > 1. Journal Articles
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.